#obesity
Related Stories (13)
Hims' obesity drug business may get boost as employers drop coverage - Reuters
Hims' obesity drug business may get boost as employers drop coverage Reuters
June 25, 2026Obesity cases rising fastest in young adults
Experts say the cost of living, pandemic and boom in unhealthy food are behind the rise in cases.
June 24, 2026UK approves Novo weight-loss pill to edge open European market - Reuters
UK approves Novo weight-loss pill to edge open European market Reuters
June 11, 2026How do weight-loss drugs like Mounjaro and Wegovy work?
Wegovy and Mounjaro are available to certain patients on the NHS, and can also be bought privately.
June 11, 2026New drug to stop 'Ozempic butt' muscle loss side effect of obesity jabs
A third of the weight loss from obesity jabs can come from muscle, say experts.
June 8, 2026Why weight-loss jabs work better for some people than others
People who carry variations in two genes linked to appetite and digestion can lose more weight when taking drugs such as Wegovy and Mounjaro to treat obesity, research suggests.
April 10, 2026New light shed on who benefits most from weight-loss jabs
People who carry variations in two genes linked to appetite and digestion can lose more weight when taking drugs to treat obesity, research suggests.
April 8, 2026India's cheap weight-loss drugs could reshape global obesity fight
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
March 18, 2026Weight-loss treatments boom as Kenyan attitudes to beauty change
Kenyan celebrities are driving a surge in weight‑loss and cosmetic procedures, sparking criticism and concerns.
March 8, 2026Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports - Reuters
Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports Reuters
March 7, 2026Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say - Reuters
Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say Reuters
February 25, 2026GPs to get £3,000 bonus to maximise weight loss drug prescriptions
Bid to improve access to Mounjaro in England, but experts warn eligibility still tightly restricted.
February 24, 2026Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial - Reuters
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial Reuters
February 23, 2026Related Pages (15)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Obesity cases rising fastest in young adults
New cases of obesity are rising fastest in younger adults in England, a study suggests. Rates of new diagnoses for people in their 30s were nearly 20% higher in 2024-25 than they were in 2019-20, acc
Wegovy weight-loss pills to be available for patients in UK to buy
Regulator approval means patients who meet criteria will be able to purchase tablets with private prescription Patients in the UK will soon be able to buy the Wegovy weight-loss pill, the medicines r
How do weight-loss drugs like Mounjaro and Wegovy work?
It is thought about 1.6 million people are on weight-loss drugs in the UK. Some patients are able to get the injections through the NHS but most buy them privately. The most popular jabs are called M
Ozempic Butt: New Drug Aims to Prevent Muscle Loss
Researchers are developing a new medication to combat muscle loss associated with popular weight loss injections. Experts say up to one-third of weight reduction from obesity jabs comes from muscle ti
AapNews.com
This domain is for sale: $4,895 Buy now for $4,895 or pay $203.96 per month for 24 months Make 24 monthly payments Pay 0% interest Start using the domain today. See details Make 24 monthly payments
New drug to stop 'Ozempic butt' muscle loss side effect of obesity jabs
A new drug called apitegromab could help people on obesity jabs avoid unwanted muscle decline that's been linked to flat bums or "Ozempic butt", according to research in Nature Medicine journal. Arou
Kenya Obesity & Weight Loss Trends: Rising Rates & Changing Attitudes
63 (adsbygoogle = window.adsbygoogle || []).push({}); A growing demand for weight-loss treatments in Kenya reflects shifting societal attitudes towards body image, alongside a concernin
Weight-Loss Surgeries And Ozempic Use Rise In Kenya As Attitudes Toward Obesity Shift
Demand for weight-loss treatments in Kenya is rising as changing social attitudes, growing health concerns, and online visibility push more people toward surgical procedures and prescription drugs suc
Bariatric surgery: A lifeline for patients battling obesity
For most of his life, Stewart Heri never thought much about his weight.Known by the nickname “Big Popper” because of his large body frame, Heri says being big had always been part of his identity sinc
Weight-loss treatments boom as Kenyan attitudes to beauty change
In Kenya, where being overweight was once perceived as a sign of wealth and success, a drive to shed the pounds is now taking hold. Surgical procedures and weight-loss drugs are growing in popularity
Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports
March 6 (Reuters) - Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health platform, bringing an end to a dispute between the two companies that escalated into a le
Dr Reddy's files 'Obeda' trademark ahead of generic ozempic launch
Hyderabad-based Dr Reddy’s Laboratories has applied to trademark the brand name and logo “Obeda”, according to sources. The proposed brand is expected to be the company’s version of semaglutide, the
GPs to get £3,000 bonus to maximise weight loss drug prescriptions
GP practices in England are to be paid an average of £3,000 a year in bonuses to prescribe patients weight loss drugs. The government is adding the incentive payments to the GP contract starting in A
Novo Nordisk’s obesity drug falls short against Eli Lilly’s in trial
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s tirzepatide in reducing